当前位置: X-MOL 学术Annu. Rev. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications.
Annual Review of Medicine ( IF 10.5 ) Pub Date : 2019-01-27 , DOI: 10.1146/annurev-med-062117-073027
Steven P Rowe 1, 2 , Michael A Gorin 1, 2 , Martin G Pomper 1, 2
Affiliation  

In recent years, small-molecule inhibitors of prostate-specific membrane antigen (PSMA) labeled with radionuclides that allow for positron emission tomography (PET) imaging have been extensively studied in many clinical contexts in men with prostate cancer (PCa). The high sensitivity and specificity of these agents for identifying sites of PCa has quickly led to their widespread adoption as a de facto clinical standard of care throughout much of the world. PSMA-targeted PET radiotracers have been particularly well-studied in preoperatively staging men with high-risk PCa, evaluating biochemical recurrence following definitive therapy, and guiding metastasis-directed therapy in patients suspected of having oligorecurrent/oligometastatic disease. Furthermore, the expression of PSMA on the tumor neovasculature of many nonprostate malignancies has enabled a burgeoning subfield concentrated on delineating the potential utility of PSMA-targeted PET agents for imaging other cancers. In this review, we highlight the preclinical development of key small molecules that are now being clinically utilized for PCa imaging, discuss the roles of PSMA-targeted agents in guiding patient management, and consider the role these compounds may play in imaging nonprostate cancers.

中文翻译:

小分子PET放射性示踪剂对前列腺特异性膜抗原的成像:从试验台到先进的临床应用。

近年来,在许多男性前列腺癌(PCa)临床环境中,对放射性核素标记的前列腺特异性膜抗原(PSMA)小分子抑制剂进行了正电子发射断层扫描(PET)成像研究。这些试剂对PCa部位的识别具有很高的敏感性和特异性,很快导致它们被广泛用作世界各地事实上的临床护理标准。针对PSMA的PET放射性示踪剂在术前分期高危PCa的男性中进行了充分的研究,评估了明确治疗后的生化复发,并在怀疑患有少复发/少转移疾病的患者中指导了转移导向的治疗。此外,PSMA在许多非前列腺恶性肿瘤的肿瘤新脉管系统上的表达已使一个新兴的子领域得以集中发展,该领域致力于描述以PSMA为靶标的PET剂对其他癌症成像的潜在效用。在这篇综述中,我们重点介绍了目前正在临床上用于PCa成像的关键小分子的临床前开发,讨论了PSMA靶向药物在指导患者治疗中的作用,并考虑了这些化合物在成像非前列腺癌中可能发挥的作用。
更新日期:2019-01-28
down
wechat
bug